Responses

Download PDFPDF
Network meta-analysis of indomethacin versus ibuprofen versus placebo for PDA in preterm infants
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Ibuprofen and Chronic lung disease association: Is this clinically significant?

    Dear Sir,

    We read the article by Jones et al with great interest describing Ibuprofen may increase the risk of chronic lung disease (CLD) compared to Indomethacin. We are unsure whether the data presented is fully supportive of the conclusion that Ibuprofen poses a greater risk of CLD compared to Indomethacin and whether this is clinically significant.

    In Figure 4 the pooled risk ratio (RR) was 1.28 (95...

    Show More
    Conflict of Interest:
    None declared.